BAHORUCO, Dominican Republic – The men in ragged clothes, many barefoot and covered in grime, scramble deep into the earth, searching for veins of a blue-green stone believed to exist only in the ...
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
The FDA is keeping its clinical hold on Larimar Therapeutics' leading candidate to treat Friedreich’s ataxia and is requesting additional data, the company announced Tuesday. In August, Larimar said ...
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
BALA CYNWYD, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its ...
Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025, focusing on ...
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results